|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
Insulin 70/30 Mix Plus Metformin Versus Triple Oral Therapy in the Treatment of Type 2 Diabetes After Failure of Two Oral Drugs
Efficacy, safety, and cost analysis
1 Diabetes and Glandular Disease Clinic, San Antonio, Texas
2 Wells Institute for Health Awareness, Kettering, Ohio
3 Princeton Junction, New Jersey
4 Novo Nordisk Pharmaceuticals, Inc., Princeton, New Jersey
5 Baylor University Medical Center, Dallas, Texas.
Address correspondence and reprint requests to Sherwyn Schwartz, MD, Diabetes and Glandular Disease Clinic, 5197 Medical Dr., San Antonio, TX 78229. E-mail: sschwartz{at}dgdclinic.com
OBJECTIVE—Subjects (n = 188) with type 2 diabetes and inadequate response to two oral medications (A1C >8.0%) were randomly assigned to treatment with either a third oral medication or an insulin 70/30 mix b.i.d. plus metformin for a comparison of efficacy, safety, and cost.
RESEARCH DESIGN AND METHODS—The protocol called for aggressive dose titration to achieve target values of fasting blood glucose (80–120 mg/dl), postprandial glucose (<160 mg/dl), and A1C (<7%). These efficacy parameters were evaluated at weeks 2, 6, 12, and 24 of therapy. If dose adjustments failed to achieve targeted glycemic control, subjects were switched to an alternate therapy.
RESULTS—At the end of study (week 24 of therapy), A1C and fasting plasma glucose (FPG) values showed comparable decreases in the two treatment groups. Only 31% (oral therapy) and 32% (insulin plus metformin) of subjects achieved target values of A1C (<7%). A total of 10 of the 98 subjects randomized to triple oral therapy (10.2%) who failed to improve sufficiently were switched to insulin therapy. An additional four subjects dropped out of the oral treatment group due to adverse events felt to be potentially drug related. Only two of the subjects randomized to insulin plus metformin had to be switched to basal-bolus regimens (regular insulin and NPH insulin). Cost analysis determined that insulin plus metformin (mean cost $3.20/day) provided efficacy equal to that of a triple oral drug regimen ($10.40/day).
CONCLUSIONS—Insulin 70/30 mix plus metformin was as effective as triple oral therapy in lowering A1C and FPG values. The triple oral regimen was not as cost effective, and a high percentage of subjects (total of 16.3%) did not complete this regimen due to lack of efficacy or side effects.
Abbreviations: FPG, fasting plasma glucose • ITT, intent-to-treat • UKPDS, U.K. Prospective Diabetes Study
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Management of Type 2 Diabetes N. Engl. J. Med., January 17, 2008; 358(3): 293 - 297. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Haas and W. Polonsky The Tipping Point: Overcoming Barriers The Diabetes Educator, July 1, 2007; 33(Supplement_7): 248S - 250S. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Achieving Glycemic Goals in Type 2 Diabetes Diabetes Care, January 1, 2007; 30(1): 174 - 180. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Davis and S. M. Renda Treating to Target in Type 2 Diabetes: A Case Presentation. The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S. [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenstock, D. Sugimoto, P. Strange, J. A. Stewart, E. Soltes-Rak, G. Dailey, and on behalf of the Insulin Glargine 4014 Study Inves Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, March 1, 2006; 29(3): 554 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Meece Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes The Diabetes Educator, January 1, 2006; 32(1): 9S - 18S. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wittlin Treating the Spectrum of Type 2 Diabetes: Emphasis on Insulin Pump Therapy The Diabetes Educator, January 1, 2006; 32(1): 39S - 46S. [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Leichter Making Outpatient Care of Diabetes More Efficient: Analyzing Noncompliance Clin. Diabetes, October 1, 2005; 23(4): 187 - 190. [Full Text] [PDF]
|
|
|
|
|
|
I. B. Hirsch, R. M. Bergenstal, C. G. Parkin, E. Wright Jr., and J. B. Buse A Real-World Approach to Insulin Therapy in Primary Care Practice Clin. Diabetes, April 1, 2005; 23(2): 78 - 86. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Schlechte Update in Endocrinology Ann Intern Med, January 18, 2005; 142(2): 126 - 131. [Full Text] [PDF]
|
|
|
|
 |
|
 Three Oral Drugs or Insulin for Type 2 Diabetic Patients? Journal Watch (General), August 19, 2003; 2003(819): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |